# Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

> **NCT06414577** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **XIANG YANQUN** · enrollment: 38 (actual)

## Conditions studied

- Nasopharyngeal Cancer

## Interventions

- **DRUG:** Irinotecan Liposomal combined With Nituzumab

## Key facts

- **NCT ID:** NCT06414577
- **Lead sponsor:** XIANG YANQUN
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-22
- **Primary completion:** 2025-03-23
- **Final completion:** 2025-03-23
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06414577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06414577, "Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06414577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*